DOI:
10.1055/s-00000094
Zeitschrift für Gastroenterologie
LinksClose Window
References
Schreiber S, Reinisch W, Colombel JF. et al.
Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn’s disease.
J Crohns Colitis 2013;
7: 213-221
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.